The estimated Net Worth of Venture Partners X, L.P.Sof... is at least $10.6 Million dollars as of 28 July 2020. Venture Sof owns over 437,500 units of Inozyme Pharma stock worth over $10,567,485 and over the last 4 years Venture sold INZY stock worth over $0.
Venture has made over 2 trades of the Inozyme Pharma stock since 2020, according to the Form 4 filled with the SEC. Most recently Venture bought 437,500 units of INZY stock worth $7,000,000 on 28 July 2020.
The largest trade Venture's ever made was buying 437,500 units of Inozyme Pharma stock on 28 July 2020 worth over $7,000,000. On average, Venture trades about 248,162 units every 14 days since 2020. As of 28 July 2020 Venture still owns at least 2,028,308 units of Inozyme Pharma stock.
You can see the complete history of Venture Sof stock trades at the bottom of the page.
Over the last 4 years, insiders at Inozyme Pharma have traded over $0 worth of Inozyme Pharma stock and bought 11,149,230 units worth $104,131,475 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, Inozyme Pharma executives and independent directors trade stock every 46 days with the average trade being worth of $2,019,505. The most recent stock trade was executed by Douglas A Treco on 1 April 2024, trading 25,000 units of INZY stock currently worth $130,250.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Inozyme Pharma executives and other stock owners filed with the SEC include: